Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3CNS 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Inflammatory Breast Neoplasms 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cyclophosphamide 80Paclitaxel 53Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Dexrazoxane × Breast × Clear all
NCT00016276 2013-01-16

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
396 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡